INFOGRAPHIC: H1 M&A from tax dodgems to asset merry-go-round
This article was originally published in Scrip
Executive Summary
Merger and acquisition activity in the biopharma sector was frenzied in the first half of 2014, and with several significant acquisitions also announced since the end of June, M&A fever shows no sign of abating in the second half.